ABIOMED, Inc. (ABMD) News
ABIOMED, Inc. (ABMD)
Today's Latest Price: $305.35 USD
Updated Aug 4 6:55pm
Add ABMD to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 132 in Medical - Devices & Equipment
See all "A" rated Strong Buy stocks
Filter ABMD News Items
ABMD News Results
| Event/Time | Symbol | Company | News Detail | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest ABMD News From Around the Web
Below are the latest news stories about Abiomed Inc that investors may wish to consider to help them evaluate ABMD as an investment opportunity.
Abiomed: Current Momentum Looks Sustainable After Year Of ControversyInvestment Thesis Abiomed 5-year share price performance. Source: TradingView The medical device industry has produced a number of notable share price winners in recent years, owing to advances in technology and the companies that have found ways to apply new technologies to augment or enhance existing medical treatments. Top-performing medical... |
FMS vs. ABMD: Which Stock Should Value Investors Buy Now?FMS vs. ABMD: Which Stock Is the Better Value Option? |
Abiomed Gets FDA Nod for Data Streaming Via Impella ConnectAbiomed's (ABMD) announcement of the FDA approval of one-way digital data streaming from the Impella Connect interface can boost patient outcomes further. |
FDA OKs data streaming from Abiomed heart pump controllerAbiomed (ABMD) announces the FDA nod for one-way digital data streaming during patient support from its Automated Impella Controller, the external console used with its Impella heart pumps.The approval allows console data to be streamed live via Impella Connect to a secure server where artificial intelligence may provide predictive clinical... |
Abiomed First Quarter Fiscal 2021 Earnings and Conference Call NotificationAbiomed announced that on Thursday, August 6, 2020, the Company will release financial results for the first quarter of fiscal 2021. |
FDA Approves Data Streaming from the Impella Console, Setting the Stage for Artificial Intelligence Algorithms to Further Improve Patient OutcomesThe United States Food and Drug Administration (FDA) has approved one-way digital data streaming during patient support from Abiomed's (NASDAQ: ABMD) Automated Impella Controller (AIC), the external console used with Impella heart pumps. The data streaming capability is facilitated through the Impella Connect interface, a HIPAA-compliant, cloud-based remote monitoring platform that is currently installed at more than 200 hospitals. The approval means console data could be streamed live via Impella Connect to a secure server where artificial intelligence (AI) could provide predictive clinical information to the patient’s physician. |
Did Hedge Funds Make The Right Call On ABIOMED, Inc. (ABMD) ?The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […] |
Are These Medical Stocks Cruising Toward Big Gains? Here's A Bullish SignMedical stocks could be making a comeback this year. The best-performing among them include medical technology companies with high Composite Ratings, a key metric measuring growth. |
MiMedx Announces Concurrent $150 Million Private Equity and Debt FinancingsMiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or “the Company”), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced the closing of concurrent $150 million private equity and debt financings, consisting of an equity financing pursuant to a Securities Purchase Agreement with an entity controlled by EW Healthcare Partners and certain funds managed by Hayfin Capital Management LLP (“Hayfin”), and a debt financing pursuant to a Loan Agreement with Hayfin. As part of the transaction, EW Healthcare Partners has designated Martin P. Sutter and William A. Hawkins III to serve on the Company’s board as preferred directors. |
Study Finds 84% Survival Rate in Patients in Cardiogenic Shock and Other Challenging Cardiac Conditions with the New Impella 5.5 with SmartAssistThe first published United States experience of patients who received Abiomed’s newest heart pump, Impella 5.5 with SmartAssist, finds 84% of the patients survived to explant with 76% native heart recovery. The study was published in the July edition of the American Society for Artificial Internal Organs (ASAIO) Journal. |
